Piramal Pharma Limited has informed the Exchange about Change in Company Secretary/Compliance Officer
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Piramal Pharma's Board meeting on 28th April 2026 approved FY2026 audited financial results. Standalone revenue declined 9.5% to Rs. 4,782 Crores but profit after tax rose 1.2% to Rs. 700 Crores with EPS of Rs. 5.28. Consolidated revenue fell 3.1% to Rs. 8,869 Crores with a net loss of Rs. 326 Crores due to Rs. 196 Crores in exceptional items (impairment and labour code impact). The Board re-appointed Ms. Nandini Piramal as Executive Director and Chairperson for 3 years from April 2027, and Mr. Peter DeYoung as Executive Director for 3 years from October 2026. Two Independent Directors (Mr. Sridhar Gorthi and Mr. Peter Stevenson) were also re-appointed for second terms. Mr. Maneesh Sharma was appointed as permanent Company Secretary and Compliance Officer from 29th April 2026, replacing interim Ms. Pratibha Mishra. The registered office address is also changing within the same locality effective 30th April 2026.
Standalone operations remain profitable despite revenue decline, but consolidated losses may create near-term stock pressure. Leadership continuity with the Piramal-DeYoung family continuing at the helm provides stability. The appointment of a permanent Company Secretary strengthens compliance governance.